ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001366

Comparison of clinical data sets acquired on different tomographs using 6-18F-L-dopa

Identifieur interne : 001366 ( PascalFrancis/Corpus ); précédent : 001365; suivant : 001367

Comparison of clinical data sets acquired on different tomographs using 6-18F-L-dopa

Auteurs : M.-J. Ribeiro ; P. Remy ; B. Bendriem ; P. Almeida ; V. Brulon ; Y. Samson ; B. Maziere ; R. Trebossen

Source :

European journal of nuclear medicine [ 0340-6997 ] ; 2000.

RBID : Pascal:00-0327398

Descripteurs français

Pascal (Inist)
- Tomoscintigraphie, Positon, Fluor, Encéphale, Système nerveux central, Homme, Lévodopa, Faisabilité, Etude comparative, Réponse instrumentale, Précision, Imagerie médicale.

English descriptors

KwdEn :
- Accuracy, Brain (vertebrata), Central nervous system, Comparative study, Emission tomography, Feasibility, Fluorine, Human, Instrumental response, Levodopa, Medical imagery, Positron.

Abstract

Longitudinal positron emission tomography (PET) studies of 6-¹⁸F-L-dopa uptake in the striatum are used to assess the progression of Parkinson's disease or the survival of neuronal cells grafted in parkinsonian patients. These studies are performed over several years, and data analysis may suffer from the change from old tomographs to new machines with better sensitivity and spatial resolution. Furthermore, such studies on parkinsonian patients may be accomplished in either 2D or 3D acquisition mode. The aforementioned improvements offer great benefits for the study of neurodegenerative diseases, especially those affecting the striatum. However, direct comparison of data is not straightforward owing to variation in scanner characteristics. In this study, we assessed the feasibility of comparing the 6-¹⁸F-L-dopa striatal uptake values (K_c) measured in two groups of healthy subjects using two tomographs of different generations. We re-studied and compared acquisitions performed on 14 healthy subjects using 6-¹⁸F-L-dopa. Half of these studies had been performed in 2D acquisition mode using an ECAT 953B. The other half had been performed in 3D acquisition mode using an ECAT EXACT HR+. Different reconstruction protocols were used and the K_c values obtained were statistically compared. The results showed that lowering the transverse spatial resolution of images obtained with the scanner having the better spatial resolution, so that it more closely matched that of the other machine, allowed similar K_c values to be obtained in healthy subjects. This study shows that quantitative results of 6-¹⁸F-L-dopa scans can be matched between different scanners with different intrinsic resolutions. This can be accomplished using adequate modifications of the reconstruction parameters. Such modifications can be used to help in the longitudinal monitoring of parkinsonian patients using different tomographs.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0340-6997`
A02	`01`			`@0 EJNMD9`
A03		`1`		`@0 Eur. j. nucl. med.`
A05				`@2 27`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Comparison of clinical data sets acquired on different tomographs using 6-¹⁸F-L-dopa`
A11	`01`	`1`		`@1 RIBEIRO (M.-J.)`
A11	`02`	`1`		`@1 REMY (P.)`
A11	`03`	`1`		`@1 BENDRIEM (B.)`
A11	`04`	`1`		`@1 ALMEIDA (P.)`
A11	`05`	`1`		`@1 BRULON (V.)`
A11	`06`	`1`		`@1 SAMSON (Y.)`
A11	`07`	`1`		`@1 MAZIERE (B.)`
A11	`08`	`1`		`@1 TREBOSSEN (R.)`
A14	`01`			`@1 CEA, Service Hospitalier Frédéric Joliot, DSV/DRM @2 Orsay @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 Serviço de Biofísica, IBILI, Faculdade de Medicina de Coimbra @2 Coimbra @3 PRT @Z 1 aut.`
A14	`03`			`@1 CTI PET Systems, Inc. @2 Knoxville, Tenn. @3 USA @Z 3 aut.`
A14	`04`			`@1 Siemens @3 FRA @Z 3 aut.`
A14	`05`			`@1 IBEF, FCL @2 Lisboa @3 PRT @Z 4 aut.`
A20				`@1 707-712`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17140 @5 354000088728800130`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 00-0327398`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 European journal of nuclear medicine`
A66	`01`			`@0 DEU`
C01	`01`		`ENG`	@0 Longitudinal positron emission tomography (PET) studies of 6-¹⁸F-L-dopa uptake in the striatum are used to assess the progression of Parkinson's disease or the survival of neuronal cells grafted in parkinsonian patients. These studies are performed over several years, and data analysis may suffer from the change from old tomographs to new machines with better sensitivity and spatial resolution. Furthermore, such studies on parkinsonian patients may be accomplished in either 2D or 3D acquisition mode. The aforementioned improvements offer great benefits for the study of neurodegenerative diseases, especially those affecting the striatum. However, direct comparison of data is not straightforward owing to variation in scanner characteristics. In this study, we assessed the feasibility of comparing the 6-¹⁸F-L-dopa striatal uptake values (K_c) measured in two groups of healthy subjects using two tomographs of different generations. We re-studied and compared acquisitions performed on 14 healthy subjects using 6-¹⁸F-L-dopa. Half of these studies had been performed in 2D acquisition mode using an ECAT 953B. The other half had been performed in 3D acquisition mode using an ECAT EXACT HR+. Different reconstruction protocols were used and the K_c values obtained were statistically compared. The results showed that lowering the transverse spatial resolution of images obtained with the scanner having the better spatial resolution, so that it more closely matched that of the other machine, allowed similar K_c values to be obtained in healthy subjects. This study shows that quantitative results of 6-¹⁸F-L-dopa scans can be matched between different scanners with different intrinsic resolutions. This can be accomplished using adequate modifications of the reconstruction parameters. Such modifications can be used to help in the longitudinal monitoring of parkinsonian patients using different tomographs.
C02	`01`	`X`		`@0 002B24B07`
C03	`01`	`X`	`FRE`	`@0 Tomoscintigraphie @5 01`
C03	`01`	`X`	`ENG`	`@0 Emission tomography @5 01`
C03	`01`	`X`	`SPA`	`@0 Tomocentelleografía @5 01`
C03	`02`	`X`	`FRE`	`@0 Positon @5 02`
C03	`02`	`X`	`ENG`	`@0 Positron @5 02`
C03	`02`	`X`	`SPA`	`@0 Positrón @5 02`
C03	`03`	`X`	`FRE`	`@0 Fluor @2 NC @2 FX @5 03`
C03	`03`	`X`	`ENG`	`@0 Fluorine @2 NC @2 FX @5 03`
C03	`03`	`X`	`SPA`	`@0 Fluor @2 NC @2 FX @5 03`
C03	`04`	`X`	`FRE`	`@0 Encéphale @5 04`
C03	`04`	`X`	`ENG`	`@0 Brain (vertebrata) @5 04`
C03	`04`	`X`	`SPA`	`@0 Encéfalo @5 04`
C03	`05`	`X`	`FRE`	`@0 Système nerveux central @5 05`
C03	`05`	`X`	`ENG`	`@0 Central nervous system @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso central @5 05`
C03	`06`	`X`	`FRE`	`@0 Homme @5 06`
C03	`06`	`X`	`ENG`	`@0 Human @5 06`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 06`
C03	`07`	`X`	`FRE`	`@0 Lévodopa @5 07`
C03	`07`	`X`	`ENG`	`@0 Levodopa @5 07`
C03	`07`	`X`	`SPA`	`@0 Levodopa @5 07`
C03	`08`	`X`	`FRE`	`@0 Faisabilité @5 08`
C03	`08`	`X`	`ENG`	`@0 Feasibility @5 08`
C03	`08`	`X`	`SPA`	`@0 Practicabilidad @5 08`
C03	`09`	`X`	`FRE`	`@0 Etude comparative @5 09`
C03	`09`	`X`	`ENG`	`@0 Comparative study @5 09`
C03	`09`	`X`	`SPA`	`@0 Estudio comparativo @5 09`
C03	`10`	`X`	`FRE`	`@0 Réponse instrumentale @5 10`
C03	`10`	`X`	`ENG`	`@0 Instrumental response @5 10`
C03	`10`	`X`	`SPA`	`@0 Respuesta instrumental @5 10`
C03	`11`	`X`	`FRE`	`@0 Précision @5 11`
C03	`11`	`X`	`ENG`	`@0 Accuracy @5 11`
C03	`11`	`X`	`SPA`	`@0 Precisión @5 11`
C03	`12`	`X`	`FRE`	`@0 Imagerie médicale @5 12`
C03	`12`	`X`	`ENG`	`@0 Medical imagery @5 12`
C03	`12`	`X`	`SPA`	`@0 Imageneria medical @5 12`
C07	`01`	`X`	`FRE`	`@0 Exploration radioisotopique @5 37`
C07	`01`	`X`	`ENG`	`@0 Radionuclide study @5 37`
C07	`01`	`X`	`SPA`	`@0 Exploración radioisotópica @5 37`
C07	`02`	`X`	`FRE`	`@0 Antiparkinsonien @5 53`
C07	`02`	`X`	`ENG`	`@0 Antiparkinson agent @5 53`
C07	`02`	`X`	`SPA`	`@0 Antiparkinsoniano @5 53`
N21				`@1 220`

Format Inist (serveur)

NO :	PASCAL 00-0327398 INIST
ET :	Comparison of clinical data sets acquired on different tomographs using 6-¹⁸F-L-dopa
AU :	RIBEIRO (M.-J.); REMY (P.); BENDRIEM (B.); ALMEIDA (P.); BRULON (V.); SAMSON (Y.); MAZIERE (B.); TREBOSSEN (R.)
AF :	CEA, Service Hospitalier Frédéric Joliot, DSV/DRM/Orsay/France (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); Serviço de Biofísica, IBILI, Faculdade de Medicina de Coimbra/Coimbra/Portugal (1 aut.); CTI PET Systems, Inc./Knoxville, Tenn./Etats-Unis (3 aut.); Siemens/France (3 aut.); IBEF, FCL/Lisboa/Portugal (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	European journal of nuclear medicine; ISSN 0340-6997; Coden EJNMD9; Allemagne; Da. 2000; Vol. 27; No. 6; Pp. 707-712; Bibl. 24 ref.
LA :	Anglais
EA :	Longitudinal positron emission tomography (PET) studies of 6-¹⁸F-L-dopa uptake in the striatum are used to assess the progression of Parkinson's disease or the survival of neuronal cells grafted in parkinsonian patients. These studies are performed over several years, and data analysis may suffer from the change from old tomographs to new machines with better sensitivity and spatial resolution. Furthermore, such studies on parkinsonian patients may be accomplished in either 2D or 3D acquisition mode. The aforementioned improvements offer great benefits for the study of neurodegenerative diseases, especially those affecting the striatum. However, direct comparison of data is not straightforward owing to variation in scanner characteristics. In this study, we assessed the feasibility of comparing the 6-¹⁸F-L-dopa striatal uptake values (K_c) measured in two groups of healthy subjects using two tomographs of different generations. We re-studied and compared acquisitions performed on 14 healthy subjects using 6-¹⁸F-L-dopa. Half of these studies had been performed in 2D acquisition mode using an ECAT 953B. The other half had been performed in 3D acquisition mode using an ECAT EXACT HR+. Different reconstruction protocols were used and the K_c values obtained were statistically compared. The results showed that lowering the transverse spatial resolution of images obtained with the scanner having the better spatial resolution, so that it more closely matched that of the other machine, allowed similar K_c values to be obtained in healthy subjects. This study shows that quantitative results of 6-¹⁸F-L-dopa scans can be matched between different scanners with different intrinsic resolutions. This can be accomplished using adequate modifications of the reconstruction parameters. Such modifications can be used to help in the longitudinal monitoring of parkinsonian patients using different tomographs.
CC :	002B24B07
FD :	Tomoscintigraphie; Positon; Fluor; Encéphale; Système nerveux central; Homme; Lévodopa; Faisabilité; Etude comparative; Réponse instrumentale; Précision; Imagerie médicale
FG :	Exploration radioisotopique; Antiparkinsonien
ED :	Emission tomography; Positron; Fluorine; Brain (vertebrata); Central nervous system; Human; Levodopa; Feasibility; Comparative study; Instrumental response; Accuracy; Medical imagery
EG :	Radionuclide study; Antiparkinson agent
SD :	Tomocentelleografía; Positrón; Fluor; Encéfalo; Sistema nervioso central; Hombre; Levodopa; Practicabilidad; Estudio comparativo; Respuesta instrumental; Precisión; Imageneria medical
LO :	INIST-17140.354000088728800130
ID :	00-0327398

Links to Exploration step

Pascal:00-0327398

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of clinical data sets acquired on different tomographs using 6-<sup>18</sup>
F-L-dopa</title>
<author><name sortKey="Ribeiro, M J" sort="Ribeiro, M J" uniqKey="Ribeiro M" first="M.-J." last="Ribeiro">M.-J. Ribeiro</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Serviço de Biofísica, IBILI, Faculdade de Medicina de Coimbra</s1>
<s2>Coimbra</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Remy, P" sort="Remy, P" uniqKey="Remy P" first="P." last="Remy">P. Remy</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bendriem, B" sort="Bendriem, B" uniqKey="Bendriem B" first="B." last="Bendriem">B. Bendriem</name>
<affiliation><inist:fA14 i1="03"><s1>CTI PET Systems, Inc.</s1>
<s2>Knoxville, Tenn.</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Siemens</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Almeida, P" sort="Almeida, P" uniqKey="Almeida P" first="P." last="Almeida">P. Almeida</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>IBEF, FCL</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brulon, V" sort="Brulon, V" uniqKey="Brulon V" first="V." last="Brulon">V. Brulon</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Samson, Y" sort="Samson, Y" uniqKey="Samson Y" first="Y." last="Samson">Y. Samson</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maziere, B" sort="Maziere, B" uniqKey="Maziere B" first="B." last="Maziere">B. Maziere</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trebossen, R" sort="Trebossen, R" uniqKey="Trebossen R" first="R." last="Trebossen">R. Trebossen</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0327398</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0327398 INIST</idno>
<idno type="RBID">Pascal:00-0327398</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001366</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of clinical data sets acquired on different tomographs using 6-<sup>18</sup>
F-L-dopa</title>
<author><name sortKey="Ribeiro, M J" sort="Ribeiro, M J" uniqKey="Ribeiro M" first="M.-J." last="Ribeiro">M.-J. Ribeiro</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Serviço de Biofísica, IBILI, Faculdade de Medicina de Coimbra</s1>
<s2>Coimbra</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Remy, P" sort="Remy, P" uniqKey="Remy P" first="P." last="Remy">P. Remy</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bendriem, B" sort="Bendriem, B" uniqKey="Bendriem B" first="B." last="Bendriem">B. Bendriem</name>
<affiliation><inist:fA14 i1="03"><s1>CTI PET Systems, Inc.</s1>
<s2>Knoxville, Tenn.</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Siemens</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Almeida, P" sort="Almeida, P" uniqKey="Almeida P" first="P." last="Almeida">P. Almeida</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>IBEF, FCL</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brulon, V" sort="Brulon, V" uniqKey="Brulon V" first="V." last="Brulon">V. Brulon</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Samson, Y" sort="Samson, Y" uniqKey="Samson Y" first="Y." last="Samson">Y. Samson</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maziere, B" sort="Maziere, B" uniqKey="Maziere B" first="B." last="Maziere">B. Maziere</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trebossen, R" sort="Trebossen, R" uniqKey="Trebossen R" first="R." last="Trebossen">R. Trebossen</name>
<affiliation><inist:fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European journal of nuclear medicine</title>
<title level="j" type="abbreviated">Eur. j. nucl. med.</title>
<idno type="ISSN">0340-6997</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European journal of nuclear medicine</title>
<title level="j" type="abbreviated">Eur. j. nucl. med.</title>
<idno type="ISSN">0340-6997</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accuracy</term>
<term>Brain (vertebrata)</term>
<term>Central nervous system</term>
<term>Comparative study</term>
<term>Emission tomography</term>
<term>Feasibility</term>
<term>Fluorine</term>
<term>Human</term>
<term>Instrumental response</term>
<term>Levodopa</term>
<term>Medical imagery</term>
<term>Positron</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Tomoscintigraphie</term>
<term>Positon</term>
<term>Fluor</term>
<term>Encéphale</term>
<term>Système nerveux central</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Faisabilité</term>
<term>Etude comparative</term>
<term>Réponse instrumentale</term>
<term>Précision</term>
<term>Imagerie médicale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Longitudinal positron emission tomography (PET) studies of 6-<sup>18</sup>
F-L-dopa uptake in the striatum are used to assess the progression of Parkinson's disease or the survival of neuronal cells grafted in parkinsonian patients. These studies are performed over several years, and data analysis may suffer from the change from old tomographs to new machines with better sensitivity and spatial resolution. Furthermore, such studies on parkinsonian patients may be accomplished in either 2D or 3D acquisition mode. The aforementioned improvements offer great benefits for the study of neurodegenerative diseases, especially those affecting the striatum. However, direct comparison of data is not straightforward owing to variation in scanner characteristics. In this study, we assessed the feasibility of comparing the 6-<sup>18</sup>
F-L-dopa striatal uptake values (K<sub>c</sub>
) measured in two groups of healthy subjects using two tomographs of different generations. We re-studied and compared acquisitions performed on 14 healthy subjects using 6-<sup>18</sup>
F-L-dopa. Half of these studies had been performed in 2D acquisition mode using an ECAT 953B. The other half had been performed in 3D acquisition mode using an ECAT EXACT HR+. Different reconstruction protocols were used and the K<sub>c</sub>
 values obtained were statistically compared. The results showed that lowering the transverse spatial resolution of images obtained with the scanner having the better spatial resolution, so that it more closely matched that of the other machine, allowed similar K<sub>c</sub>
 values to be obtained in healthy subjects. This study shows that quantitative results of 6-<sup>18</sup>
F-L-dopa scans can be matched between different scanners with different intrinsic resolutions. This can be accomplished using adequate modifications of the reconstruction parameters. Such modifications can be used to help in the longitudinal monitoring of parkinsonian patients using different tomographs.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0340-6997</s0>
</fA01>
<fA02 i1="01"><s0>EJNMD9</s0>
</fA02>
<fA03 i2="1"><s0>Eur. j. nucl. med.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Comparison of clinical data sets acquired on different tomographs using 6-<sup>18</sup>
F-L-dopa</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RIBEIRO (M.-J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>REMY (P.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BENDRIEM (B.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ALMEIDA (P.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BRULON (V.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SAMSON (Y.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MAZIERE (B.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>TREBOSSEN (R.)</s1>
</fA11>
<fA14 i1="01"><s1>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Serviço de Biofísica, IBILI, Faculdade de Medicina de Coimbra</s1>
<s2>Coimbra</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>CTI PET Systems, Inc.</s1>
<s2>Knoxville, Tenn.</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Siemens</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>IBEF, FCL</s1>
<s2>Lisboa</s2>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>707-712</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17140</s2>
<s5>354000088728800130</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0327398</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>European journal of nuclear medicine</s0>
</fA64>
<fA66 i1="01"><s0>DEU</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Longitudinal positron emission tomography (PET) studies of 6-<sup>18</sup>
F-L-dopa uptake in the striatum are used to assess the progression of Parkinson's disease or the survival of neuronal cells grafted in parkinsonian patients. These studies are performed over several years, and data analysis may suffer from the change from old tomographs to new machines with better sensitivity and spatial resolution. Furthermore, such studies on parkinsonian patients may be accomplished in either 2D or 3D acquisition mode. The aforementioned improvements offer great benefits for the study of neurodegenerative diseases, especially those affecting the striatum. However, direct comparison of data is not straightforward owing to variation in scanner characteristics. In this study, we assessed the feasibility of comparing the 6-<sup>18</sup>
F-L-dopa striatal uptake values (K<sub>c</sub>
) measured in two groups of healthy subjects using two tomographs of different generations. We re-studied and compared acquisitions performed on 14 healthy subjects using 6-<sup>18</sup>
F-L-dopa. Half of these studies had been performed in 2D acquisition mode using an ECAT 953B. The other half had been performed in 3D acquisition mode using an ECAT EXACT HR+. Different reconstruction protocols were used and the K<sub>c</sub>
 values obtained were statistically compared. The results showed that lowering the transverse spatial resolution of images obtained with the scanner having the better spatial resolution, so that it more closely matched that of the other machine, allowed similar K<sub>c</sub>
 values to be obtained in healthy subjects. This study shows that quantitative results of 6-<sup>18</sup>
F-L-dopa scans can be matched between different scanners with different intrinsic resolutions. This can be accomplished using adequate modifications of the reconstruction parameters. Such modifications can be used to help in the longitudinal monitoring of parkinsonian patients using different tomographs.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B24B07</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Positon</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Positron</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Positrón</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Fluor</s0>
<s2>NC</s2>
<s2>FX</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Fluorine</s0>
<s2>NC</s2>
<s2>FX</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Fluor</s0>
<s2>NC</s2>
<s2>FX</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Faisabilité</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Feasibility</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Practicabilidad</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Réponse instrumentale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Instrumental response</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Respuesta instrumental</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Précision</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Accuracy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Precisión</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Imagerie médicale</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Medical imagery</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Imageneria medical</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Radionuclide study</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>53</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>53</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>53</s5>
</fC07>
<fN21><s1>220</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 00-0327398 INIST</NO>
<ET>Comparison of clinical data sets acquired on different tomographs using 6-<sup>18</sup>
F-L-dopa</ET>
<AU>RIBEIRO (M.-J.); REMY (P.); BENDRIEM (B.); ALMEIDA (P.); BRULON (V.); SAMSON (Y.); MAZIERE (B.); TREBOSSEN (R.)</AU>
<AF>CEA, Service Hospitalier Frédéric Joliot, DSV/DRM/Orsay/France (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); Serviço de Biofísica, IBILI, Faculdade de Medicina de Coimbra/Coimbra/Portugal (1 aut.); CTI PET Systems, Inc./Knoxville, Tenn./Etats-Unis (3 aut.); Siemens/France (3 aut.); IBEF, FCL/Lisboa/Portugal (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>European journal of nuclear medicine; ISSN 0340-6997; Coden EJNMD9; Allemagne; Da. 2000; Vol. 27; No. 6; Pp. 707-712; Bibl. 24 ref.</SO>
<LA>Anglais</LA>
<EA>Longitudinal positron emission tomography (PET) studies of 6-<sup>18</sup>
F-L-dopa uptake in the striatum are used to assess the progression of Parkinson's disease or the survival of neuronal cells grafted in parkinsonian patients. These studies are performed over several years, and data analysis may suffer from the change from old tomographs to new machines with better sensitivity and spatial resolution. Furthermore, such studies on parkinsonian patients may be accomplished in either 2D or 3D acquisition mode. The aforementioned improvements offer great benefits for the study of neurodegenerative diseases, especially those affecting the striatum. However, direct comparison of data is not straightforward owing to variation in scanner characteristics. In this study, we assessed the feasibility of comparing the 6-<sup>18</sup>
F-L-dopa striatal uptake values (K<sub>c</sub>
) measured in two groups of healthy subjects using two tomographs of different generations. We re-studied and compared acquisitions performed on 14 healthy subjects using 6-<sup>18</sup>
F-L-dopa. Half of these studies had been performed in 2D acquisition mode using an ECAT 953B. The other half had been performed in 3D acquisition mode using an ECAT EXACT HR+. Different reconstruction protocols were used and the K<sub>c</sub>
 values obtained were statistically compared. The results showed that lowering the transverse spatial resolution of images obtained with the scanner having the better spatial resolution, so that it more closely matched that of the other machine, allowed similar K<sub>c</sub>
 values to be obtained in healthy subjects. This study shows that quantitative results of 6-<sup>18</sup>
F-L-dopa scans can be matched between different scanners with different intrinsic resolutions. This can be accomplished using adequate modifications of the reconstruction parameters. Such modifications can be used to help in the longitudinal monitoring of parkinsonian patients using different tomographs.</EA>
<CC>002B24B07</CC>
<FD>Tomoscintigraphie; Positon; Fluor; Encéphale; Système nerveux central; Homme; Lévodopa; Faisabilité; Etude comparative; Réponse instrumentale; Précision; Imagerie médicale</FD>
<FG>Exploration radioisotopique; Antiparkinsonien</FG>
<ED>Emission tomography; Positron; Fluorine; Brain (vertebrata); Central nervous system; Human; Levodopa; Feasibility; Comparative study; Instrumental response; Accuracy; Medical imagery</ED>
<EG>Radionuclide study; Antiparkinson agent</EG>
<SD>Tomocentelleografía; Positrón; Fluor; Encéfalo; Sistema nervioso central; Hombre; Levodopa; Practicabilidad; Estudio comparativo; Respuesta instrumental; Precisión; Imageneria medical</SD>
<LO>INIST-17140.354000088728800130</LO>
<ID>00-0327398</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001366 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001366 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:00-0327398
   |texte=   Comparison of clinical data sets acquired on different tomographs using 6-18F-L-dopa
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Comparison of clinical data sets acquired on different tomographs using 6-18F-L-dopa

Comparison of clinical data sets acquired on different tomographs using 6-18F-L-dopa

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri